Drug intelligence / Profile preview

TKD-004

Development stage: Unknown
Lead developer: Therakind
Modality: Peptides
Administration: Intranasal

Overview

TKD-004 is an intranasal peptide therapeutic being developed by Therakind for the treatment of hypoglycaemia (hypoglycaemic episodes). The drug utilizes a nasal delivery route, which is intended to provide a non-invasive and rapid-acting alternative to injectable treatments for severe low blood sugar, particularly in pediatric or emergency settings. As of the latest reports, Therakind has completed preclinical development and clinical proof-of-concept studies for this asset. The peptide is likely a glucagon receptor agonist, designed to stimulate the release of glucose from the liver to reverse hypoglycaemia.

Targets

GCGR (Glucagon receptor)

Beyond the preview

Go deeper on TKD-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TKD-004.

Explore the full profile